Retatrutide is an investigational injectable medication being developed by Eli Lilly as a potential treatment for obesity and type 2 diabetes
Food & Drug Administration (2021) Insulin resistance, Cleveland Clinic (2021) The potential role of incretin-based therapies for polycystic ovary syndrome: A narrative review of the current evidence, Sage Journals (2021) Impact of obesity on infertility in women, Journal of the Turkish-German Gynecological Association (2015) Semaglutide treatment of excessive body weight in obese PCOS patients unresponsive to lifestyle programs, Journal of Clinical Medicine (2023) Semaglutide vs metformin in polycystic ovary syndrome (PCOS), Clinicaltrials.gov (2024) Short-term exenatide treatment leads to significant weight loss in a subset of obese women without diabetes, Diabetes Car e (2012) Liraglutide for weight management: a critical review of the evidence, Obesity Science and Practice (2017) Polycystic ovary syndrome: Common questions and answers, American Family Physician (2023) Insulin resistance in polycystic ovarian syndrome, Cureus ( 2022) Hirsutism, Mayo Clinic (2021) Medically accurate: SingleCares Medical Review Board analyzes all of our content to confirm its in line with current medical advice
Clinical trials may involve different patient populations, doses, treatment lengths, diabetes status, lifestyle support, and study designs
Most patients notice appetite reduction within the first 12 weeks of starting GLP-1 medication
Plus, a balanced diet plays a key role in enhancing the effectiveness of GLP-1s
PubMed Horne, C., Supramaniam, A., Lamont, B., Parkinson, J., Park, J.E., Vath, J., et al
